Login / Signup

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

Colleen Gc McGregorAlex AdamsRoss SadlerCarolina V Arancibia-CárcamoRebecca PalmerTim AmbroseOliver BrainAlissa WalshPaul KlenermanSimon P L TravisNicholas M CroftJames O LindsayJack Satsangi
Published in: Gut (2021)
Keyphrases
  • sars cov
  • ulcerative colitis
  • respiratory syndrome coronavirus
  • coronavirus disease
  • patients with inflammatory bowel disease
  • stem cells
  • cell therapy